Home / Journals International Journal of Neurosurgery / Immunotherapy and Brain Tumors
Immunotherapy and Brain Tumors
Submission DeadlineDec. 25, 2019

Online submission system: http://www.sciencepublishinggroup.com/login

Lead Guest Editor
Cynthia Kassab
The University of Texas MD Anderson Cancer Center,  Houston, USA
Guest Editors
  • Eric Holland
    Fred Hutchinson Cancer Research Center and UW Medicine, Washington, USA
  • Sanaalarab Al Enazy
    The University of Texas MD Anderson Cancer Center, Houston, USA
  • Dolores Hambardzumyan
    Emory University School of Medicine, Atlanta, USA
  • Hussein Tawbi
    The University of Texas MD Anderson Cancer Center,  Houston, USA
  • Pravesh Gupta
    The University of Texas MD Anderson Cancer Center,  Houston, USA
  • Lynette Phillips
    The University of Texas MD Anderson Cancer Center,  Houston, USA
  • Marc Daou
    Department of Neurosurgery, MD Anderson Cancer Center, Houston, USA
Introduction
“William Bradley Coley, surgeon, medical discoverer, and director of medical research; who learned to cure by surgery ills that foiled its art. And without surgery, others beyond its reach.”-Harvard University 1911 upon receiving his degree of Honorary Master of Arts.
This special issue focuses on understanding brain tumors. It includes topics regarding benign and malignant brain tumors, with an emphasis on brain metastases as the most common brain tumors overall, and on gliomas as the most common primary tumors of the central nervous system. It covers epidemiology data, translational research and clinical implications, from bench to bedside. This issue discusses fundamental scientific mechanisms behind the development and evolution of brain tumors such as driver mutations, epigenetics and potential risk factors. Clinical impression of brain tumors are also discussed and correlated to tumor location and subtype with a focus on the new WHO molecular classification of gliomas. For so long, the central nervous system was believed, like the eye, to be “immunologically privileged”, which means its immune system has its own defenses and does not rely on the systemic immunity to fight a disease. In fact, this phenomenon emanated from our anatomo-histological ignorance of that territory. Currently, our understanding of the brain opened the door to the application of systemic therapies and has proven to be successful, for example the discovery of immune checkpoint inhibitors for the treatment of malignant melanoma with brain metastases. What are the mechanisms behind this success? Did it succeed in different types of brain cancer? And why?
This issue addresses these questions and provides information on current practices in the treatment of brain tumors, more specifically immunotherapy outcomes and updates on successful and ongoing clinical trials.
Aims and Scope:
  1. Primary brain tumors
  2. Brain metastasis
  3. Brain blood barrier
  4. Immunotherapy
  5. Glioma/Glioblastoma
  6. Current treatment for brain tumors
  7. Brain tumors genomic analysis
  8. CAR-T therapy
  9. Tumor microenvironment
  10. Nanoparticles
  11. Translational research
  12. Clinical trials
  13. Immune Checkpoints
Guidelines for Submission
Manuscripts should be formatted according to the guidelines for authors
(see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=524).

Please download the template to format your manuscript.

ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186